Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Case Comprehensive Cancer Center
With
National Cancer Institute (NCI)
Mitaka USA, Inc.
PRIMARY OBJECTIVES:
I. To confirm that axillary lymphatic mapping with indocyanine green solution (ICG) solution leads to a similar number of nodes being labeled as sentinel as lymphatic mapping with 99mTc-labeled (technetium Tc-99m sulfur colloid) radiotracer.
OUTLINE:
Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo axillary sentinel node biopsy and surgery.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer
Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy
Participants with planned axillary sentinel node biopsy procedure
You may not be if
Participants with cancer \> 3 cm
Participants with clinically positive nodes
Participants with prior surgery for breast cancer in the index breast
Participants who have had bilateral breast surgeries
